AaiPharma Gains on FDA Action
Shares of up-and-down aaiPharma (AAII)went up Friday after the Food and Drug Administration approved its request for a broader application of its methadone product.
In late trading, the Wilmington, N.C.-based company's stock gained 97 cents, or 5.2%, to reach $19.67. The stock had risen as high as $19.90.
Analysts said Friday that although methadone is not a big contributor to aaiPharma's sales, the FDA's action comes several months earlier than had been expected. The company's injectable version of methadone is used to treat moderate to severe pain in patients for whom non-narcotic analgesics are ineffective and to temporarily treat opiate-dependent patients who can't take pills.
The company's stock has been on a mostly downward plunge in recent days due to disappointing financial results, some analysts' concerns about inventories, the faster-than-expected FDA approval of a competitor's generic version of an aaiPharma painkiller, and the departure of the company's chief operating officer for the CEO job at another drug company.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV